SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as the market reacts to a landmark joint venture between AT&T, Verizon, and T-Mobile to expand direct-to-device satellite connectivity, fueling speculation that ASTS will serve as the essential infrastructure layer for these major carriers. While the stock experiences high volatility, the community is actively debating the significance of these carrier partnerships and the potential for a major short squeeze as investors look ahead to upcoming satellite launch milestones.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is facing intense retail scrutiny and bearish sentiment after management announced a pivot to slow down Ethereum accumulation, sparking concerns over dilution and a potential shift in strategy. While institutional investors monitor the stock's tight correlation with ETH, community discussion remains heavily divided between those holding for a long-term crypto turnaround and frustrated traders who are losing confidence in leadership's aggressive growth targets.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as the community actively discusses the stock's recent GPO partnership and potential for commercial traction, while weighing these developments against persistent concerns regarding management's history of dilution and the company's capital burn. Investors are closely monitoring weekly prescription data and upcoming earnings reports, debating whether current commercial progress justifies the stock's valuation or indicates continued financial instability.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors react to strong earnings and raised EBITDA guidance, while the community actively discusses the stock's significant long-term growth potential and its strategic importance in the ongoing global LNG supply disruption. Traders are closely monitoring the impact of Middle East geopolitical tensions and potential price target upgrades as they anticipate a breakout beyond current resistance levels.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is experiencing significant trading activity driven by its expanding role in AI and EV chip reliability testing, with investors closely watching its revenue growth and capacity expansion in Malaysia. The community is actively debating the company's valuation relative to larger sector peers, with many focusing on the potential for a fundamental re-rating amid strong order flow and a relatively small float.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors prepare for pivotal extended Phase 3 data for CAN-2409, with the community closely monitoring the upcoming plenary presentation for evidence of practice-changing efficacy in prostate cancer. Market participants are actively discussing the stock's significant institutional support, potential for a premium buyout by Big Pharma, and the ongoing tension between optimistic long-term holders and aggressive short-selling activity.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is generating significant market buzz as it pivots from a residential solar company into a provider of power solutions for AI data centers, with investors closely watching its IQ Solid-State Transformer technology. The community is actively debating whether this strategic shift will trigger a major long-term energy cycle or if the stock's recent volatility is merely a reaction to technical trading patterns and broader sector shifts.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, United Online (UOL), and Consumer Products. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Lingo segment offers a global cloud or unified communications and managed service provider to Enterprise and Small to Medium Businesses in the United States. The magicJack VoIP segment is a non-interconnected Voice-over-IP (VoIP) cloud-based communications service provider that offers related devices and subscription services within the United States and Canada. The Marcon segment is a mobile virtual network operator that provides mobile phone voice, text, and data services and devices using the Credo Mobile brand. The United Online segment is an Internet access provider that offers dial-up and digital subscriber line services under the NetZero and Juno brands across the United States. The Consumer Products segment generates revenue through sales of laptop and computer accessories. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors focus on its significant embedded gains in holdings like Babcock & Wilcox and Applied Digital, fueling debates about a potential sum-of-the-parts re-rating. While the community remains divided over management's debt and dividend strategy, the stock is drawing attention due to its high short interest and the anticipation of upcoming quarterly results.

SolarEdge Technologies, Inc. engages in the development of energy technology, which provides inverter solutions. The firm operates through the following segments: Solar and All Other. The Solar segment includes the design, development, manufacturing, and sales of an inverter solution designed to maximize power generation. The All Other segment includes the design, development, manufacturing and sales of UPS products, energy storage products, e-Mobility products, and automated machines. Its products and services include photovoltaic inverters, power optimizers, photovoltaic monitoring, software tools, and electric vehicle chargers. The company was founded by Guy Sella, Lior Handelsman, Yoav Galin, Meir Adest, and Amir Fishelov on August 7, 2006 and is headquartered in Herzliya, Israel.

Solaredge Technologies Inc

SolarEdge is experiencing significant market interest driven by a strategic shift toward AI data center power infrastructure and energy optimization, alongside a technical short squeeze. Community sentiment is sharply divided, with some investors betting on a long-term turnaround fueled by new product launches and AI demand, while others remain skeptical, citing fundamental challenges and potential volatility.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant volatility and heavy short pressure as investors debate the impact of aggressive consolidation efforts, including the recent Kodiak acquisition and the proposed $17 billion TopBuild merger. While some in the community remain deeply committed to the long-term vision of CEO Brad Jacobs to create a dominant building products platform, others are expressing frustration over persistent downward price trends, potential dilution, and broader macro headwinds in the housing and consumer sectors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Tonmya is the first U.S. Food and Drug Administration-approved treatment for fibromyalgia in adults in more than 15 years.</li><li>The drug is a non-opioid therapy for daily bedtime use to manage chronic pain.</li><li>Investors are also focusing on TNX-4800, Tonix’s antibody to prevent Lyme disease.</li></ul>Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) drew strong retail interest on Wednesday, rising about 7% after the company announced a new agreement with a major group purchasing organization to broaden access to its fibromyalgia treatment.Fibromyalgia is a chronic pain condition affecting mostly women, marked by widespread pain, fatigue, poor sleep, and cognitive and mood issues.<h2 class="st-heading-2">TNXP Bets Big On Tonmya</h2>The deal opens coverage for its Tonmya drug to roughly 35 million commercially insured patients in the U.S. Tonmya, launched in November 2025, is the first U.S. Food and Drug Administration (FDA) approved treatment for fibromyalgia in adults in more than 15 years. It is a non-opioid therapy for daily bedtime use to manage chronic pain over the long term.The agreement marks steady progress in Tonix’s push to broaden patient access. The company is also advancing discussions with Medicare and Medicaid.“Fibromyalgia patients have experienced dissatisfaction with available therapies, with 85% of first-line treatments failing due to efficacy and tolerability issues. We are committed to providing patient access to Tonmya by continuing to engage with commercial payers on its value and offering a patient support program to help patients access their prescribed medication,” said Seth Lederman, President and CEO.<h2 class="st-heading-2">Lyme Disease Treatment Also In Focus</h2>Investors are also focusing on TNX-4800, Tonix’s long-acting antibody to prevent Lyme disease. The company plans to begin a Phase 2 randomized, double-blind, placebo-controlled field study. It is expected to test a two-dose regimen, with an initial injection in spring followed by a booster in summer.The main goal is to evaluate protection against Lyme disease over a six-month period. Tonix expects to have study drug supply ready in early 2027, with further testing, including a human challenge study, planned for 2028.<h2 class="st-heading-2">TNXP: How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/TNXP">TNXP</a> on Stocktwits turned ‘extremely bullish’ from bullish’ a day earlier, while message volumes remained ‘high.’One user said the latest partnership could add at least $30 million in annual revenue.<stembedurl>https://stocktwits.com/Pipipopopipi/message/652420353</stembedurl>However, another user expressed disappointment that the stock couldn’t break $15, given the “huge announcement.”<stembedurl>https://stocktwits.com/StockJayC/message/652434435</stembedurl>The stock has declined more than 16% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nvax-stock-rising-novavax-royalties-growth-pfizer-deal/cZQz4flReOR">Novavax Tops Expectations On High-Margin Deals – Retail Says ‘It’s The Only Thing That Matters’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNXP Stock Climbs 7%: Retail Bets On $30M Revenue Upside From Tonmya Deal

The company announced a new agreement with a major group purchasing organization which opens coverage for its Tonmya drug to roughly 35 million commercially insured patients in the U.S.

Why TNXP Stock Is Suddenly Back On Retail Radar

Equity

Why Tonix Pharmaceuticals Shares Are Rallying Wednesday

Tonix Pharmaceuticals Holding shares are trading higher Wednesday after announcing commercial payer coverage for fibromyalgia drug TONMYA.read more...

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Upgraded by TD Cowen

TD Cowen raised Tonix Pharmaceuticals to a "strong-buy" rating in a report on Tuesday...

Tonix Pharmaceuticals (TNXP) to Release Quarterly Earnings on Monday

Tonix Pharmaceuticals (NASDAQ:TNXP) will be releasing its Q1 2026 earnings before the market opens on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-tonix-pharmaceuticals-holding-corp-stock...

<ul class="summary-bullets"><li>Overall net revenue from sales in Q1 was $8.3 million, the company said.&nbsp;</li><li>The company said that it now has funds to sustain itself till the second quarter of 2027.</li><li>Total net revenue from sales of Tonmya since launch through the end of the first quarter was $5.1 million. &nbsp;</li></ul> Shares of Tonix Pharmaceuticals (TNXP) fell 3% after hours after the company said that it expects a wider preliminary net loss for the first quarter of 2026 and revenue of $3.7 million for its newly launched drug Tonmya.The company said on Friday that it expects a Q1 net loss of about $40.8 million compared to a loss of $16.8 million for the corresponding quarter of 2025.<h2 class="st-heading-2">TNXP’s Preliminary Numbers</h2>Q1 net revenue from sales of its treatments Zembrace SymTouch, and Tosymra for the quarter ended March 31, 2026, was approximately $3.2 million, compared to $2.4 million for the quarter ended March 31, 2025.Net revenue from sales of Tonmya for the quarter was approximately $3.7 million. Tonmya, an FDA-approved, non-opioid medication designed to treat fibromyalgia in adults, was launched in November 2025.Total net revenue from sales of Tonmya since launch through the end of the first quarter was $5.1 million, Tonix said. &nbsp;The company said that it ended the first quarter with about $185.5 million in cash and cash equivalents, which, together with net proceeds of $17.4 million that it raised in April 2026 to be enough to sustain it till the second quarter of 2027.The company is now slated to report its full financial results on May 11.<h2 class="st-heading-2">How Did TNXP Retail Traders React?</h2>On Stocktwits, retail sentiment around TNXP stock stayed in the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.A Stocktwits user opined that the numbers put forth by Tonix are being “misunderstood” and Tonmya launch is not “as weak as it appears.”<stembedurl>https://www.stocktwits.com/ltinvestorx/message/652073834</stembedurl>Another user opined that the company entered 2026 with real momentum and a stronger balance sheet than many of its small-cap biotech peers.<stembedurl>https://www.stocktwits.com/ACMTrader/message/652072480</stembedurl><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> fell 25% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/celc-stock-jumps-after-hours-on-positive-breast-cancer-trial-update/cZQ8HuEReeM">CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug

The company said on Friday that it now expects a net loss for the first quarter of about $40.8 million compared to a loss of $16.8 million for the corresponding quarter of 2025.

Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell

Wall Street Zen cut shares of Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Sunday...

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...

Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action?

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a fresh 52-week low as investors weigh a new SEC filing alongside a biotech pipeline update from...

Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Lowered to "Sell" at Wall Street Zen

Wall Street Zen lowered shares of Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Tonix is now evaluating its Tonmya drug for the treatment of major depressive disorder and acute stress disorder/acute stress reaction.&nbsp;</li><li>The company also expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease.</li><li>According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’.</li></ul>Shares of Tonix Pharmaceuticals (TNXP) fell for the fourth consecutive day on Friday but stayed on the radar of retail investors on Stocktwits who gauged the company’s drug pipeline.Retail chatter around the stock rose 92% over the past 24 hours. Overall, retail sentiment around the stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A user said that the company should cut spending and focus resources on expanding the indication for the company’s FDA-approved drug Tonmya.<stembedurl>https://www.stocktwits.com/ByBi/message/648804308</stembedurl>Another user voiced optimism for the company’s Tonmya drug but noted that the stock is “super diluted.”<stembedurl>https://www.stocktwits.com/BlakeCanyon50/message/648764035</stembedurl>Yet another user voiced optimism for good news while adding that they think it is “very close.”<stembedurl>https://www.stocktwits.com/pickles14/message/648794046</stembedurl><h2 class="st-heading-2">Drug Approvals</h2>The U.S. Food and Drug Administration approved Tonix’s Tonmya for the management of fibromyalgia in adults in August. The non-opioid drug launched in November and through Feb. 27, more than 1,500 healthcare providers prescribed it to patients. About 2,500 patients have initiated treatment with Tonmya, the company said earlier this month.The company is now evaluating the potential of the drug in treating major depressive disorder and acute stress disorder/acute stress reaction.<h2 class="st-heading-2">Other Pipeline Updates</h2>Tonix expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease. There are no FDA-approved vaccines or prophylactics for the disease now.Other candidates in its pipeline include TNX-2900 for the treatment of Prader-Willi syndrome, TNX-1500 for the prevention of kidney transplant rejection, and TNX-1900 for the treatment of migraines.According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’. The 12-month average price target on the stock is $54.33, representing a potential upside of about 322%.<a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> has dropped 52% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-nearly-halved-in-past-year-but-wall-street-sees-almost-500-percent-upside/cZ3HgAcRImK">ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff

On Stocktwits, retail chatter around the stock rose 92% over the past 24 hours as users contemplated on the company’s approved drugs and investigational therapy candidates. 

Investors are navigating a mix of impressive prescription growth and product revenue alongside intense debates over high cash burn and continuous equity dilution.

Increased institutional holdings and significant 13G filings have triggered a wave of speculative buying as followers look to track big money movements.

Retail bulls are actively looking for a squeeze setup, branding the current price action as a shakeout while monitoring intense volatility in the 13-15 dollar range.

Data trackers are heavily scrutinizing weekly prescription numbers as the key indicator for long-term commercial success and path to potential profitability.

Investors remain polarized over management’s commitment to early-stage pipeline assets versus the core commercial strategy for their newly launched flagship product.

TNXP
Tonix Pharmaceuticals Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest TNXP News

TNXPTonix Pharmaceuticals Holding Corp